ClinicalTrials.gg
CompletedNCT03181451Updated Oct 6, 2021Results posted

Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency

A Phase 1 interventional study of Ferric Maltol in Iron Deficiency, Anaemia in Children and Iron-Deficiency, sponsored by Shield Therapeutics. Completed at 7 sites in United Kingdom. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-06.

Sponsored by Shield Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.

Enrollment
12th of 19
37 · median 50
Started
2017
with 2 others
Phase 1
2 of 22
none open now
Registered
17th of 22
by date

Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 17th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Iron Deficiencies with a site in United Kingdom, or all of them as a file.
02

Study summary

The study has been designed to establish the pharmacokinetics (PK) and iron uptake of Ferric Maltol in children and adolescents aged 10-17 years using two (2) lower dose strengths in comparison to the EU-approved 30mg BID dose in adults with IDA in IBD.

Read the detailed description

Phase I, open label, randomized, repeat dose, multicentre, pharmacokinetic study to assess the Safety and Tolerability of Ferric Maltol in 3 different dosages.

36 eligible patients will be randomized in a 1:1:1 ratio to one of the following 3 dosages for 9 days BID and a single dose on Day 10:

  • 30mg ferric maltol capsules
  • 16.6 mg ferric maltol capsules
  • 7.8 mg ferric maltol capsules

Subject participation in the study will consist of 3 stages:

Screening: up to 14 days Treatment period: 10 days treatment period with 2 visits on Day 1 and Day 10 for PK blood sampling. Patients will be randomly allocated to one of the three Ferric Maltol dose groups according to centralized treatment allocation scheme.

Post-treatment Safety Follow-up:3-10 days following completion of the treatment period or premature discontinuation of study medication

03

Conditions studied

  • Iron Deficiency, Anaemia in Children
  • Iron-Deficiency
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the information given in the Independent Ethics Committee (IEC) approved Information Sheet and Consent form. The parent or guardian of the study subject must sign and date the and authorisation to use protected health information (PHI) in accordance with national and local subject privacy regulations prior to any study mandated procedure. The study participant will be asked to provide their assent to participate in the study using the IEC approved Assent form.
  2. Willing and able to comply with study requirements.
  3. Age ≥10 to ≤17 years at the time of informed consent and throughout duration of the study.
  4. A current diagnosis of iron deficiency (with or without anaemia); iron deficiency defined by ferritin \<30 µg/L, or ferritin \<50 µg/L with transferrin saturation (TSAT) \<20%, as measured by the central laboratory at the Screening visit (subjects with or without anaemia may be enrolled providing is ≥8.5 g/dL as measured at the Screening visit).
  5. Where appropriate, female subjects of must agree to use a reliable method of until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, a vasectomized partner and oral contraceptive medications.

Exclusion criteria

Exclusion Criteria:

  1. Has untreated or untreatable severe malabsorption syndrome e.g., untreated coeliac disease
  2. Has received within 28 days prior to Screening intramuscular or intravenous (IV) injection or administration of depot iron preparation.
  3. Has received oral iron supplementation within 7 days prior to Screening
  4. Has received blood transfusion within 12 weeks prior to Screening or is scheduled to have blood transfusion or donations during the study period.
  5. Has concomitant disease that would significantly compromise iron absorption or absorbed iron utilisation such as swallowing disorders and/or extensive small bowel resection.
  6. Has chronic renal disease ( \<30mL/min), as assessed at Screening based on serum creatinine.
  7. Known or allergy to either the active substance or of Ferric Maltol capsules.
  8. Has a known for treatment with iron preparations, e.g. haemochromatosis, chronic haemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia.
  9. Impaired liver function as indicated by (ALT) or aspartate transaminase (AST)>2.0 times upper normal limit as measured at the Screening visit.
  10. Active acute inflammatory disease, including IBD flare or disease exacerbation, which in the opinion of the Investigator, is .
  11. Active chronic or acute infectious diseases requiring antibiotic treatment.
  12. Pregnant or breast feeding.
  13. Concomitant medical conditions with extensive active bleeding, other than menstrual cycles; subjects who suffer from menorrhagia may be included at the Investigator's discretion.
  14. Scheduled or expected hospitalisation and/or surgery during the course of the study
  15. Participation in any other interventional clinical study within 28 days prior to Screening.
  16. Cardiovascular, liver, renal, hematologic, psychiatric, neurologic, gastrointestinal, immunologic, endocrine, metabolic, respiratory or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or objectives of the study drug or severely limit the lifespan of the subject.
  17. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor make the subject unsuitable for enrolment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    30 mg Ferric Maltol

    12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 \& Day 10.

    Drug: Ferric Maltol

  • Active comparator
    16.6 mg Ferric Maltol

    12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 \& Day 10.

    Drug: Ferric Maltol

  • Active comparator
    7.8 mg Ferric Maltol

    12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 \& Day 10.

    Drug: Ferric Maltol

Interventions

  • To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.

    Also known as: ST10, Feraccru

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1

    Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  2. Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10

    Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  3. Area Under The Curve [AUC] of Maltol Glucuronide on Day 1

    Descriptive statistics and population PK analysis of maltol glucuronide AUC from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  4. Area Under The Curve [AUC] of Maltol Glucuronide on Day 10

    Descriptive statistics and population PK analysis of maltol AUC from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  5. Average Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 10

    Descriptive statistics and population PK analysis of maltol glucuronide Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  6. Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 1

    Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  7. Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 10

    Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  8. Half Life [t1/2] of Maltol Glucuronide on Day 1

    Descriptive statistics and population PK analysis of maltol glucuronide t1/2 from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  9. Ratio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 1

    Descriptive statistics of ratio maltol glucuronide Cmax Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  10. Ratio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 1

    Descriptive statistics of ratio maltol glucuronide AUC Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  11. Average Serum Concentration [Cave(0-6h)] of Iron on Day 10

    Descriptive statistics and population PK analysis of iron Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  12. Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 1

    Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  13. Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10

    Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  14. Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 1

    Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  15. Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 10

    Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  16. Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1

    Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  17. Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10

    Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  18. Apparent Systemic Clearance (CL/F) of Iron on Day 1

    Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 1

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  19. Apparent Systemic Clearance (CL/F) of Iron on Day 10

    Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 10

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  20. Apparent Volume of Distribution (V/F) of Iron on Day 1

    Descriptive statistics and population PK analysis of iron V/F from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  21. Apparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 1

    Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 1

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  22. Apparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 10

    Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 10

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  23. Ratio Auc(0-6) Maltol Glucuronide Day 10/Day 1

    Ratio AUC0-6h measured after last dose of Ferric Maltol on Day 10 vs first dose Day 1.

    Time frame: Day 1 to Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  24. Serum Iron - RAUC(0-6h) D10/D1

    Serum Iron - RAUC(0-6h) Day 10/Day 1

    Time frame: Measured after first and last dose of Ferric Maltol on Day 1 & Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  25. Transferrin Saturation (%) Day 1, Baseline

    Transferrin Saturation (TSAT%) Day 1, baseline

    Time frame: Measured after first dose of Ferric Maltol on Day 1 (0h)

  26. Transferrin Saturation (%) Day 1, Maximum Response (%)

    Transferrin Saturation (TSAT%) Day 1, maximum response (%)

    Time frame: Measured after first dose of Ferric Maltol on Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  27. Transferrin Saturation Day 1, Time to Maximum Response Tmax

    Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Measured after first dose of Ferric Maltol on Day 1. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  28. Transferrin Saturation (%) Day 10, Maximum Response (%)

    Transferrin Saturation (TSAT%) Day 10, maximum response (%). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  29. Transferrin Saturation Day 10, Time to Maximum Response Tmax

    Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Measured after first dose of Ferric Maltol on Day 10. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h).

  30. AUC0-inf Day 1 for Maltol Glucuronide

    AUC0-inf for Maltol Glucuronide from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Measured after first dose of Ferric Maltol on Day 1 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  31. AUC0-tau Day 10 for Maltol Glucuronide

    AUC0-tau for Maltol Glucuronide from PK samples collected on Day 10. Area under the plasma concentration versus time curve from time 0 to tau.

    Time frame: Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  32. Cthrough for Maltol Glucuronide Day 10

    Change from pre-dose to last PK samples collected on Day 10 for maltol glucuronide.Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 10 pre-dose to last (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  33. Serum Iron Cmax Day 1

    Maximum serum concentration of serum iron on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

    Time frame: Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  34. Serum Iron Cmax on Day 10

    Maximum serum concentration of serum iron on Day 10.

    Time frame: Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  35. Plasma Maltol Glucuronide Cthrough D10/Day1

    Minimum concentration between dose time and dose time+TAU

    Time frame: Day 10 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  36. Apparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 1

    Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 1

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

  37. Apparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 10

    Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 10

    Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

  38. Apparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 1

    Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 1.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

  39. Apparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 10

    Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 10.

    Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

Secondary outcomes

  1. Transferrin - Change From Baseline to Day 10, Predose

    Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose

    Time frame: Day 1 pre-dose to Day 10 pre-dose (0h on each day)

  2. Ferritin - Change From Baseline to Day 10, Predose

    Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose.

    Time frame: Pre-dose on Day 1 to Day 10 (0h)

  3. Total Iron Binding Capacity - Change From Day 1 to Day 10, Predose

    Change calculated as difference in values measured at Day 1, predose and on Day 10, predose

    Time frame: Predose from Day 1 to Day 10 (0h on each day)

  4. UIBC - Change From Day 1 to Day 10, Predose

    Change calculated as difference in values measured at Day 1, predose and on Day 10, predose

    Time frame: Pre-dose on Day 1 to Day 10 (0h each day)

  5. Negative and Positive NTBI Tests on Day 1

    Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 1, predose

    Time frame: Day 1 (0h)

  6. Change From Baseline to Day 10 in Haemoglobin Concentration

    Change calculated as difference in values measured at Screening (Baseline) and on Day 10

    Time frame: Screening and Day 10 (1-4 hours post-dose)

  7. Change From Baseline to Day 10 in Absolute Reticulocyte Count

    Change from Baseline to Day 10 in Absolute Reticulocyte Count collected from PK samples

    Time frame: Change calculated as difference in values measured at Screening (Baseline) and on Day 10.

  8. Treatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments

    Descriptive summary of incidence and causal relationship of treatment-emergent adverse events leading to discontinuation of study drug/PK assessments according to MedDRA preferred term (PT) and system organ class (SOC)

    Time frame: From first dose of Ferric Maltol on Day 1 through study completion, on average 4 weeks

  9. Changes in 12-lead ECG Parameters From Screening to Day 10

    Overall clinical interpretation of routine ECG parameters from Screening to Day 10

    Time frame: Screening and Day 10 (1-4 hours post-dose)

  10. Concomitant Medications

    Number of subjects with concomitant medications Taken by \>5% of Subjects

    Time frame: Screening, Day 1, Day 10 and Post-Study Follow-up visit, on average 4 weeks

  11. Negative and Positive NTBI Tests on Day 10, Predose

    Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 10, predose

    Time frame: Day 10

  12. Treatment-emergent Serious Adverse Event (TESAE)

    Descriptive summary of TESAE according to MedDRA preferred Term

    Time frame: From first dose of ferric maltol Day 1 through study completions, on average 4 weeks

07

Results

Posted Jun 2, 2020

Participant flow

Participant flow — Overall Study
Milestone30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Started121312
Completed121112
Not completed020
Withdrew: Adverse event010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryMaximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1

Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 12.4518 ± 1.295901.1632 ± 0.184350.5299 ± 0.02245
PrimaryMaximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10

Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 104.2355 ± 0.781102.1028 ± 0.133420.9926 ± 0.02349
PrimaryArea Under The Curve [AUC] of Maltol Glucuronide on Day 1

Descriptive statistics and population PK analysis of maltol glucuronide AUC from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*mg/L
Area Under The Curve [AUC] of Maltol Glucuronide on Day 1
h*mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Area Under The Curve [AUC] of Maltol Glucuronide on Day 111.090 ± 3.90335.613 ± 0.75892.585 ± 0.0968
PrimaryArea Under The Curve [AUC] of Maltol Glucuronide on Day 10

Descriptive statistics and population PK analysis of maltol AUC from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*mg/L
Area Under The Curve [AUC] of Maltol Glucuronide on Day 10
h*mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Area Under The Curve [AUC] of Maltol Glucuronide on Day 1020.511 ± 1.799710.518 ± 0.52775.016 ± 0.1133
PrimaryAverage Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 10

Descriptive statistics and population PK analysis of maltol glucuronide Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Average Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 10
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Average Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 103.4186 ± 0.299951.7531 ± 0.087950.8360 ± 0.01889
PrimaryTime of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 1

Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Median · h
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 1
h30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 11.00 (0.75 to 1.00)1.00 (0.75 to 1.00)1.00 (1.00 to 1.00)
PrimaryTime of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 10

Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Median · h
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 10
h30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 100.75 (0.75 to 0.75)0.75 (0.75 to 0.75)0.75 (0.75 to 0.75)
PrimaryHalf Life [t1/2] of Maltol Glucuronide on Day 1

Descriptive statistics and population PK analysis of maltol glucuronide t1/2 from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h
Half Life [t1/2] of Maltol Glucuronide on Day 1
h30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Half Life [t1/2] of Maltol Glucuronide on Day 111.384 ± 5.473810.447 ± 1.850310.806 ± 0.4707
PrimaryRatio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 1

Descriptive statistics of ratio maltol glucuronide Cmax Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · ratio
Ratio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 1
ratio30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Ratio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 11.956 ± 0.62101.836 ± 0.21091.875 ± 0.0537
PrimaryRatio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 1

Descriptive statistics of ratio maltol glucuronide AUC Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · ratio
Ratio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 1
ratio30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Ratio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 12.030 ± 0.66951.899 ± 0.22861.942 ± 0.0582
PrimaryAverage Serum Concentration [Cave(0-6h)] of Iron on Day 10

Descriptive statistics and population PK analysis of iron Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Average Serum Concentration [Cave(0-6h)] of Iron on Day 10
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Average Serum Concentration [Cave(0-6h)] of Iron on Day 101.1667 ± 0.614200.9557 ± 0.296450.9748 ± 0.39783
PrimaryChange From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 1

Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 1
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10.6159 ± 0.323200.4102 ± 0.221440.21715 ± 0.11873
PrimaryChange From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10

Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10
mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 100.5486 ± 0.323670.3625 ± 0.153330.2251 ± 0.08362
PrimaryPre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 1

Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*mg/L
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 1
h*mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 16.711 ± 2.57215.963 ± 1.77933.928 ± 1.1318
PrimaryPre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 10

Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*mg/L
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 10
h*mg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 107.000 ± 3.68525.734 ± 1.77875.849 ± 2.3870
PrimaryPre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1

Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*%
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1
h*%30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1179.47 ± 60.259159.21 ± 50.723104.50 ± 41.009
PrimaryPre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10

Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h*%
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10
h*%30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10180.14 ± 76.193149.40 ± 37.799157.43 ± 81.693
PrimaryApparent Systemic Clearance (CL/F) of Iron on Day 1

Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 1

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · L/h
Apparent Systemic Clearance (CL/F) of Iron on Day 1
L/h30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Apparent Systemic Clearance (CL/F) of Iron on Day 11.321 ± 0.69450.654 ± 0.24410.324 ± 0.1517
PrimaryApparent Systemic Clearance (CL/F) of Iron on Day 10

Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 10

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · L/h
Apparent Systemic Clearance (CL/F) of Iron on Day 10
L/h30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Apparent Systemic Clearance (CL/F) of Iron on Day 103.264 ± 2.22971.757 ± 0.66730.808 ± 0.3089
PrimaryApparent Volume of Distribution (V/F) of Iron on Day 1

Descriptive statistics and population PK analysis of iron V/F from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · L
Apparent Volume of Distribution (V/F) of Iron on Day 1
L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Apparent Volume of Distribution (V/F) of Iron on Day 122.114 ± 7.231514.244 ± 4.808310.462 ± 3.1033
PrimaryApparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 1

Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 1

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 10

Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 10

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

No measurements were reported for this outcome.

PrimaryRatio Auc(0-6) Maltol Glucuronide Day 10/Day 1

Ratio AUC0-6h measured after last dose of Ferric Maltol on Day 10 vs first dose Day 1.

Time frame:
Day 1 to Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · Ratio
Ratio Auc(0-6) Maltol Glucuronide Day 10/Day 1
Ratio7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Ratio Auc(0-6) Maltol Glucuronide Day 10/Day 11.942 ± 0.05821.899 ± 0.22862.030 ± 0.6695
PrimarySerum Iron - RAUC(0-6h) D10/D1

Serum Iron - RAUC(0-6h) Day 10/Day 1

Time frame:
Measured after first and last dose of Ferric Maltol on Day 1 & Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · Ratio
Serum Iron - RAUC(0-6h) D10/D1
Ratio7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Serum Iron - RAUC(0-6h) D10/D11.529 ± 1.46731.020 ± 0.31701.038 ± 0.3973
PrimaryTransferrin Saturation (%) Day 1, Baseline

Transferrin Saturation (TSAT%) Day 1, baseline

Time frame:
Measured after first dose of Ferric Maltol on Day 1 (0h)
Reported as:
Mean · percentage saturation
Transferrin Saturation (%) Day 1, Baseline
percentage saturation7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Transferrin Saturation (%) Day 1, Baseline11.5 ± 5.6616.8 ± 9.2515.8 ± 9.31
PrimaryTransferrin Saturation (%) Day 1, Maximum Response (%)

Transferrin Saturation (TSAT%) Day 1, maximum response (%)

Time frame:
Measured after first dose of Ferric Maltol on Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · percentage saturation
Transferrin Saturation (%) Day 1, Maximum Response (%)
percentage saturation7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Transferrin Saturation (%) Day 1, Maximum Response (%)18.68 ± 7.1328.261 ± 8.478432.845 ± 10.5913
PrimaryTransferrin Saturation Day 1, Time to Maximum Response Tmax

Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Measured after first dose of Ferric Maltol on Day 1. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Median · hour
Transferrin Saturation Day 1, Time to Maximum Response Tmax
hour7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Transferrin Saturation Day 1, Time to Maximum Response Tmax4.00 (2.00 to 4.00)3.00 (2.00 to 4.00)3.00 (3.00 to 5.00)
PrimaryTransferrin Saturation (%) Day 10, Maximum Response (%)

Transferrin Saturation (TSAT%) Day 10, maximum response (%). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · percentage saturation
Transferrin Saturation (%) Day 10, Maximum Response (%)
percentage saturation7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Transferrin Saturation (%) Day 10, Maximum Response (%)27.779 ± 13.86327.214 ± 6.69933.524 ± 13.633
PrimaryTransferrin Saturation Day 10, Time to Maximum Response Tmax

Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Measured after first dose of Ferric Maltol on Day 10. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h).
Reported as:
Median · hour
Transferrin Saturation Day 10, Time to Maximum Response Tmax
hour7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Transferrin Saturation Day 10, Time to Maximum Response Tmax3.00 (0.00 to 4.00)3.00 (0.00 to 4.00)3.00 (0.00 to 4.00)
PrimaryAUC0-inf Day 1 for Maltol Glucuronide

AUC0-inf for Maltol Glucuronide from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Measured after first dose of Ferric Maltol on Day 1 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h.mg/L
AUC0-inf Day 1 for Maltol Glucuronide
h.mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
AUC0-inf Day 1 for Maltol Glucuronide8.590 ± 0.202517.862 ± 0.932834.372 ± 4.5052
PrimaryAUC0-tau Day 10 for Maltol Glucuronide

AUC0-tau for Maltol Glucuronide from PK samples collected on Day 10. Area under the plasma concentration versus time curve from time 0 to tau.

Time frame:
Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · h mg/L
AUC0-tau Day 10 for Maltol Glucuronide
h mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
AUC0-tau Day 10 for Maltol Glucuronide8.59 ± 0.202417.862 ± 0.932734.368 ± 4.4981
PrimaryCthrough for Maltol Glucuronide Day 10

Change from pre-dose to last PK samples collected on Day 10 for maltol glucuronide.Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 10 pre-dose to last (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Cthrough for Maltol Glucuronide Day 10
mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Cthrough for Maltol Glucuronide Day 100.4804 ± 0.016390.9762 ± 0.105861.8496 ± 0.67761
PrimarySerum Iron Cmax Day 1

Maximum serum concentration of serum iron on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.

Time frame:
Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Serum Iron Cmax Day 1
mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Serum Iron Cmax Day 10.7030 ± 0.197651.681 ± 0.304051.2328 ± 0.47471
PrimarySerum Iron Cmax on Day 10

Maximum serum concentration of serum iron on Day 10.

Time frame:
Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Serum Iron Cmax on Day 10
mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Serum Iron Cmax on Day 101.0338 ± 0.40231.0462 ± 0.32211.3034 ± 0.6741
PrimaryPlasma Maltol Glucuronide Cthrough D10/Day1

Minimum concentration between dose time and dose time+TAU

Time frame:
Day 10 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Reported as:
Mean · mg/L
Plasma Maltol Glucuronide Cthrough D10/Day1
mg/L7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Plasma Maltol Glucuronide Cthrough D10/Day10.4804 ± 0.01630.9762 ± 0.1051.8496 ± 0.677
PrimaryApparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 1

Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 1

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

No measurements were reported for this outcome.

PrimaryApparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 10

Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 10

Time frame:
Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)

No measurements were reported for this outcome.

SecondaryTransferrin - Change From Baseline to Day 10, Predose

Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose

Time frame:
Day 1 pre-dose to Day 10 pre-dose (0h on each day)
Reported as:
Mean · g/L
Transferrin - Change From Baseline to Day 10, Predose
g/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Transferrin - Change From Baseline to Day 10, Predose-0.085 ± 0.1510-0.147 ± 0.14190.032 ± 0.2275
SecondaryFerritin - Change From Baseline to Day 10, Predose

Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose.

Time frame:
Pre-dose on Day 1 to Day 10 (0h)
Reported as:
Mean · μg/L
Ferritin - Change From Baseline to Day 10, Predose
μg/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Ferritin - Change From Baseline to Day 10, Predose7.3 ± 8.224.1 ± 3.730.5 ± 4.95
SecondaryTotal Iron Binding Capacity - Change From Day 1 to Day 10, Predose

Change calculated as difference in values measured at Day 1, predose and on Day 10, predose

Time frame:
Predose from Day 1 to Day 10 (0h on each day)
Reported as:
Mean · umol/L
Total Iron Binding Capacity - Change From Day 1 to Day 10, Predose
umol/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Total Iron Binding Capacity - Change From Day 1 to Day 10, Predose-2.12 ± 3.406-3.11 ± 3.2011.13 ± 4.452
SecondaryUIBC - Change From Day 1 to Day 10, Predose

Change calculated as difference in values measured at Day 1, predose and on Day 10, predose

Time frame:
Pre-dose on Day 1 to Day 10 (0h each day)
Reported as:
Mean · umol/L
UIBC - Change From Day 1 to Day 10, Predose
umol/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
UIBC - Change From Day 1 to Day 10, Predose-2.10 ± 7.775-2.33 ± 5.525-4.49 ± 8.343
SecondaryNegative and Positive NTBI Tests on Day 1

Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 1, predose

Time frame:
Day 1 (0h)
Reported as:
Count of participants · Participants
Negative and Positive NTBI Tests on Day 1
Participants30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Positive000
Negative121312
SecondaryChange From Baseline to Day 10 in Haemoglobin Concentration

Change calculated as difference in values measured at Screening (Baseline) and on Day 10

Time frame:
Screening and Day 10 (1-4 hours post-dose)
Reported as:
Mean · g/dL
Change From Baseline to Day 10 in Haemoglobin Concentration
g/dL30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Change From Baseline to Day 10 in Haemoglobin Concentration-0.03 ± 0.789-0.33 ± 1.097-0.45 ± 0.301
SecondaryChange From Baseline to Day 10 in Absolute Reticulocyte Count

Change from Baseline to Day 10 in Absolute Reticulocyte Count collected from PK samples

Time frame:
Change calculated as difference in values measured at Screening (Baseline) and on Day 10.
Reported as:
Mean · cells*10^12/L
Change From Baseline to Day 10 in Absolute Reticulocyte Count
cells*10^12/L30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Change From Baseline to Day 10 in Absolute Reticulocyte Count0.036 ± 0.0114-0.001 ± 0.02180.016 ± 0.0358
SecondaryTreatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments

Descriptive summary of incidence and causal relationship of treatment-emergent adverse events leading to discontinuation of study drug/PK assessments according to MedDRA preferred term (PT) and system organ class (SOC)

Time frame:
From first dose of Ferric Maltol on Day 1 through study completion, on average 4 weeks
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments
Participants30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Treatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments010
SecondaryChanges in 12-lead ECG Parameters From Screening to Day 10

Overall clinical interpretation of routine ECG parameters from Screening to Day 10

Time frame:
Screening and Day 10 (1-4 hours post-dose)
Reported as:
Count of participants · Participants
Changes in 12-lead ECG Parameters From Screening to Day 10
Participants30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Normal101112
Abnormal000
SecondaryConcomitant Medications

Number of subjects with concomitant medications Taken by \>5% of Subjects

Time frame:
Screening, Day 1, Day 10 and Post-Study Follow-up visit, on average 4 weeks
Reported as:
Count of participants · Participants
Concomitant Medications
Participants30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Concomitant Medications81310
SecondaryNegative and Positive NTBI Tests on Day 10, Predose

Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 10, predose

Time frame:
Day 10
Reported as:
Count of participants · Participants
Negative and Positive NTBI Tests on Day 10, Predose
Participants30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
Positive100
Negative111110
SecondaryTreatment-emergent Serious Adverse Event (TESAE)

Descriptive summary of TESAE according to MedDRA preferred Term

Time frame:
From first dose of ferric maltol Day 1 through study completions, on average 4 weeks
Reported as:
Count of participants · Participants
Treatment-emergent Serious Adverse Event (TESAE)
Participants7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric Maltol
Treatment-emergent Serious Adverse Event (TESAE)000
PrimaryApparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 1

Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 1.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

No measurements were reported for this outcome.

PrimaryApparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 10

Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 10.

Time frame:
Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h

No measurements were reported for this outcome.

Adverse events

Collected over 10 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
30 mg Ferric Maltol0/12 (0%)0/12 (0%)7/12 (58.3%)
16.6 mg Ferric Maltol0/13 (0%)0/13 (0%)7/13 (53.8%)
7.8 mg Ferric Maltol0/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 29
Most frequent other events
Event30 mg Ferric Maltol16.6 mg Ferric Maltol7.8 mg Ferric Maltol
HeadacheNervous system disorders4/122/131/12
Faeces discolouredGastrointestinal disorders3/121/131/12
DiarrhoeaGastrointestinal disorders1/120/132/12
FatigueGeneral disorders2/121/131/12
DizzinessNervous system disorders2/121/130/12
PalpitationsCardiac disorders0/120/131/12
NauseaGastrointestinal disorders1/120/131/12
VomitingGastrointestinal disorders0/121/131/12
Abdominal distensionGastrointestinal disorders1/120/130/12
Abdominal painGastrointestinal disorders1/120/130/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Mean14.1 ± 1.5613.7 ± 1.8014.2 ± 2.1214.0 ± 1.80
Age, Customized
Age, Customized(Participants)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
10-1487823
15-1746414
Sex: Female, Male
Sex: Female, Male(Participants)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Female88824
Male45413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Ethnicity — Not Hispanic or Latino11131135
Ethnicity — Unknown1012
Height
Height(m)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Mean1.590 ± 0.06411.601 ± 0.8551.618 ± 0.09141.603 ± 0.0799
Weight
Weight(kg)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Mean57.83 ± 20.96162.77 ± 23.33052.07 ± 9.66157.41 ± 18.758
BMI
BMI(kg/m^2)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Mean22.695 ± 7.406724.265 ± 7.764719.760 ± 2.704922.182 ± 6.4355
Haemoglobin
Haemoglobin(g/dL)7.8 mg Ferric Maltol16.6 mg Ferric Maltol30 mg Ferric MaltolTotal
Mean12.27 ± 0.85612.75 ± 1.06712.37 ± 1.41812.47 ± 1.124

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L14 5AB, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2PG, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
  • Nottingham University Hospital
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Mar 2018, 12 months.

Results were first posted in Jun 2020, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
Jun 8, 2017
StartActual
Mar 14, 2017
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results first posted
Jun 2, 2020
Last update
Oct 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03181451
Lead sponsor
Shield Therapeutics
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Mar 14, 2017
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Jun 2, 2020
Last update
Oct 6, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion